Caprino L, Borrelli F, Falchetti R, Cafiero C, Gandolfo G M
Haemostasis. 1977;6(5):310-7. doi: 10.1159/000214196.
The effect of ditazole, a new antiaggregant oxazole derivative as well as its possible interaction with urokinase on the formation of electrically induced thrombus, was assayed in rabbits. The activity of ditazole in reducing thrombus weight was comparable to that of aspirin. In the ditazole- or aspirin-treated animals, the microscopical examination of the thrombus showed a reduction in the fibrin component, and well-isolated platelets not undergoing a viscous metamorphosis were present. Urokinase, administered in combination with these antiaggregant drugs, did not induce a further reduction in thrombus weight. However, this additional treatment did induce clearly visible lytic areas and histological modifications as observed with the antiaggregant drugs. These data suggest that the antiplatelet drug ditazole may be an effective antithrombotic agent in man and could facilitate the penetration of urokinase into the thrombus.
在兔身上测定了新型抗聚集恶唑衍生物双苯唑的作用，以及它与尿激酶在电诱导血栓形成过程中可能的相互作用。双苯唑减轻血栓重量的活性与阿司匹林相当。在接受双苯唑或阿司匹林治疗的动物中，血栓的显微镜检查显示纤维蛋白成分减少，并且存在未发生粘性变形的分离良好的血小板。与这些抗聚集药物联合使用的尿激酶，并未进一步减轻血栓重量。然而，这种额外的治疗确实诱导出了清晰可见的溶解区域以及抗聚集药物所观察到的组织学改变。这些数据表明，抗血小板药物双苯唑可能是一种对人类有效的抗血栓形成药物，并且可能促进尿激酶渗透到血栓中。
